Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
Private credit may have been hit by negative headlines, but inflows are unquestionably strong, says Sanjay Jhamna, Head of Global Credit Trading at JPMorgan. He says the fact that recent AI model releases did not result in a negative market reaction shows that the shock has passed for the software sector. Jhamna joined "The Pulse with Francine Lacqua" at the JPMorgan's Global Markets Conference in...
Private credit may have been hit by negative headlines, but inflows are unquestionably strong, says Sanjay Jhamna, Head of Global Credit Trading at JPMorgan. He says the fact that recent AI model releases did not result in a negative market reaction shows that the shock has passed for the software sector. Jhamna joined "The Pulse with Francine Lacqua" at the JPMorgan's Global Markets Conference in Paris. (Source: Bloomberg)
Galeh Kholis Pambudi/iStock via Getty Images As a long term, value-oriented investor, I don't mind underperforming the market, even if it is for an extended window of time. The most important thing is that, in the long run, I beat the market by a measurable degree. If I can't do that, I may as well just put my money an index fund and spend my time more productively. This mindset that I have is why...
Galeh Kholis Pambudi/iStock via Getty Images As a long term, value-oriented investor, I don't mind underperforming the market, even if it is for an extended window of time. The most important thing is that, in the long run, I beat the market by a measurable degree. If I can't do that, I may as well just put my money an index fund and spend my time more productively. This mindset that I have is why I don't mind the fact that, since I called Crown Holdings ( CCK ) a ‘buy’ back in November of last year, the stock has underperformed the market. Shares are up 6.7%, which means that the firm has trailed the 10.7% rise that the S&P 500 experienced over the same window of time. Some of this underperformance is understandable. Although the company is seeing some nice revenue growth, some profitability metrics have worsened as of late. But others are solid, and the stock seems to be trading at a low price both on an absolute basis and relative to other similar companies. In light of this, I have no problem maintaining it as a ‘buy’ candidate right now. Not ready to throw in the towel As a company that operates plants dedicated to producing metal cans and ends for the beverage, food, and aerosol industries, not to mention as a producer of other packaging related products and solutions like those involving steel, paper, and plastic, Crown Holdings might not seem all that exciting a prospect right now. After all, the company is not some high growth tech play. It never will be. That's fine with me. What matters more is that I view it as a fundamentally attractive firm that is trading on the cheap. And that is precisely what we have here. Author - SEC EDGAR Data The best way to prove this would be to look at the most recent data that management has made available. This is data covering the first quarter of the company's 2026 fiscal year . In the chart above, you can see that revenue for the business came in at $3.26 billion. That happens to be 12.9% above the $2.89 billion that th...
(RTTNews) - The London stock market's benchmark FTSE 100 fell on Tuesday as stocks shed ground amid concerns over fading prospects of a U.S.-Iran peace deal, rising oil prices and political uncertainty in the UK.
(RTTNews) - The London stock market's benchmark FTSE 100 fell on Tuesday as stocks shed ground amid concerns over fading prospects of a U.S.-Iran peace deal, rising oil prices and political uncertainty in the UK.
Traffic in the Strait of Hormuz remains at a standstill, with the US President saying the ceasefire is on "massive life support". Dubravko Lakos, Global Head of Market Strategy at JPMorgan, says inventories have helped to offset to the energy shock so far, but we're now heading towards so-called "operational stress levels" that could potentially force the reopening of the Strait. Lakos joined Bloo...
Traffic in the Strait of Hormuz remains at a standstill, with the US President saying the ceasefire is on "massive life support". Dubravko Lakos, Global Head of Market Strategy at JPMorgan, says inventories have helped to offset to the energy shock so far, but we're now heading towards so-called "operational stress levels" that could potentially force the reopening of the Strait. Lakos joined Bloomberg's Francine Lacqua at JPMorgan's Global Markets Conference in Paris. (Source: Bloomberg)
Luis Alvarez/DigitalVision via Getty Images Investment overview I wrote about LegalZoom ( LZ ) previously with a hold rating as I was not confident in the setup back then despite acknowledging that subscription growth had accelerated and ARPU had turned positive. For this earnings update, I think the higher-value subscription strategy now looks more tangible, and the partner channel is clearly gai...
Luis Alvarez/DigitalVision via Getty Images Investment overview I wrote about LegalZoom ( LZ ) previously with a hold rating as I was not confident in the setup back then despite acknowledging that subscription growth had accelerated and ARPU had turned positive. For this earnings update, I think the higher-value subscription strategy now looks more tangible, and the partner channel is clearly gaining traction. That said, this Q1 was still helped by some timing and lapping benefits, while margin remained weak. And hence, I still think the setup is not enough to justify an upgrade yet. Q1 2026 earnings Total revenue came in at $206.8 million, with subscription revenue at $130.2 million, and transaction revenue at $76.6 million. Growth was 13% y/y, 12% y/y, and 15% respectively. On the subscription side, growth came from better monetization. Subscription units were 1.92 million, flat y/y, while ARPU grew 4%. The pricing strength came from higher registered agent revenue (after the pricing actions), higher legal advisory subscription revenue from bundling into certain formation offers, and contributions from virtual mail and concierge. Transaction revenue did well as transaction units grew 10% to 375,000, business formations were up 8% to 142,000, and average order value [AOV] was also up 5% to $205. That said, total operating expenses went up accordingly as well, to $129.5 million from $107.6 million in Q1 2025, and that magnitude was bigger than the topline growth. This led to EBIT falling to $2.8 million from $9 million, and adj. EBITDA falling 1% y/y to $36.5 million. The higher-value revenue strategy I think the main takeaway I had from this quarter was that the higher-value subscription story that I noted previously is easier to underwrite. Previously, the idea made sense, but a lot of it felt more theoretical. But now we have tangible numbers to back this idea. Registered agent subscription revenue was up 17% because of pricing, and legal advisory subscription r...
Madison Air Solutions Corporation press release ( MAIR ): Q1 Revenue of $923.7M (+33.8% Y/Y) beats by $74.7M . Backlog up 115.5% year-over-year and orders up 29.1% on a combined basis*** Net sales of $923.7 million, up 33.8%, including 12.5% on a pro forma basis** Net income of $43.0 million, down 6.9%, adjusted net income* up 32.1% Adjusted EBITDA* of $233.4 million, up 38.7%, with adjusted EBITD...
Madison Air Solutions Corporation press release ( MAIR ): Q1 Revenue of $923.7M (+33.8% Y/Y) beats by $74.7M . Backlog up 115.5% year-over-year and orders up 29.1% on a combined basis*** Net sales of $923.7 million, up 33.8%, including 12.5% on a pro forma basis** Net income of $43.0 million, down 6.9%, adjusted net income* up 32.1% Adjusted EBITDA* of $233.4 million, up 38.7%, with adjusted EBITDA margin* of 25.3%, up 89 bps Full-Year 2026 Guidance Current Guidance** Net Sales $3,750 to $3,850 million Adjusted EBITDA* $1,020 to $1,065 million Click to enlarge More on Madison Air Solutions Corporation Madison Air Solutions: Good Growth, But Overvalued Stock Madison Air Solutions: Providing Better Air, Obtaining Premium Valuations Madison Air Solutions Targets Large IPO To Pay Down Debt Goldman Sachs cuts IPO forecast; biggest IPOs since 2025 ranked by market cap Madison Air pops 19% in blockbuster IPO, taps AI-driven data center boom
Niklas Östberg , the chief executive officer of German food delivery company Delivery Hero SE , will step down after an activist investor that’s called for him to leave raised its stake in the company. Östberg, who co-founded Delivery Hero in 2011, will step down by March 31, 2027 at the latest, the company said in a statement Tuesday. The supervisory board aims to complete its search for a succes...
Niklas Östberg , the chief executive officer of German food delivery company Delivery Hero SE , will step down after an activist investor that’s called for him to leave raised its stake in the company. Östberg, who co-founded Delivery Hero in 2011, will step down by March 31, 2027 at the latest, the company said in a statement Tuesday. The supervisory board aims to complete its search for a successor by year-end. His resignation comes after Prosus NV , Delivery Hero’s largest shareholder, this week said it is selling a 5% stake to Hong Kong-based Aspex Management , which will boost its holding to about 14%. Aspex has been pushing Östberg to offload more assets or leave the company. Delivery Hero shares pared earlier losses and were down 0.2% to €23.55 at 12:59 p.m. in Frankfurt. That’s compared to over €130 at its 2021 peak. The development caps a 15-year tenure for Östberg, who was co-CEO before becoming the sole leader. Östberg used debt to fuel rapid expansion through acquisitions such as Glovo and Woowa to build a portfolio of brands and franchises in about 65 countries. Delivery Hero said last December that it’s evaluating options to improve finances and operations after Bloomberg reported that the company was facing pressure from investors including Aspex to conduct a strategic review amid increasing consolidation in the food-delivery industry. In March, Aspex Management said it would try and replace the food delivery company’s management if it doesn’t push ahead with the sale of some assets. Delivery Hero that month sold its Taiwan food delivery operations to Grab for $600 million. Read More: Delivery Hero Holder Aspex Tells CEO to Sell Units or Leave
Although the benchmark S&P 500 (SNPINDEX: ^GSPC) and Nasdaq Composite (NASDAQINDEX: ^IXIC) vaulted to new highs on May 8, this wasn't the only history made on Wall Street last week. The stock market's largest projected initial public offering (IPO) , Elon Musk's SpaceX, hit an all-time high on private market trading platform Forge Global, which was acquired in early March by Charles Schwab . The $...
Although the benchmark S&P 500 (SNPINDEX: ^GSPC) and Nasdaq Composite (NASDAQINDEX: ^IXIC) vaulted to new highs on May 8, this wasn't the only history made on Wall Street last week. The stock market's largest projected initial public offering (IPO) , Elon Musk's SpaceX, hit an all-time high on private market trading platform Forge Global, which was acquired in early March by Charles Schwab . The $634.05 closing price per share for SpaceX stock on Forge's secondary marketplace represents a 215% increase over the trailing 12 months and values the company at $1.51 trillion. Image source: Getty Images. Continue reading
Legend Biotech press release ( LEGN ): Q1 GAAP EPS of -$0.15 beats by $0.02 . Revenue of $305.1M (+56.4% Y/Y) misses by $1.42M . Collaboration revenue was $298.4 million for the three months ended March 31, 2026, compared to $185.6 million for the three months ended March 31, 2025. The increase of $112.8 million was due to an increase in revenue generated from sales of CARVYKTI ® in connection wit...
Legend Biotech press release ( LEGN ): Q1 GAAP EPS of -$0.15 beats by $0.02 . Revenue of $305.1M (+56.4% Y/Y) misses by $1.42M . Collaboration revenue was $298.4 million for the three months ended March 31, 2026, compared to $185.6 million for the three months ended March 31, 2025. The increase of $112.8 million was due to an increase in revenue generated from sales of CARVYKTI ® in connection with the Janssen collaboration and license agreement (the “Janssen Agreement”). Cash and cash equivalents, and time deposits were $834.6 million as of March 31, 2026. More on Legend Biotech Legend Biotech: Undervalued Leader In The CAR-T Race Legend Biotech Corporation (LEGN) Q4 2025 Earnings Call Transcript Legend Biotech Corporation 2025 Q4 - Results - Earnings Call Presentation Legend Biotech Q1 2026 Earnings Preview Healthcare quant check: RLAY and TNGX lead Seeking Alpha’s top picks ahead of Q1 earnings
Just_Super/iStock via Getty Images IREN ( IREN ) reported its Q3‘26 results on May 7, 2026 which showcased that the company’s transition to AI Cloud Services is picking up steam. In addition to a generally well-regarded earnings report for the third fiscal quarter, IREN inked a massive $3.4B, 5-year AI cloud contract with Nvidia ( NVDA ) which is contingent upon the AI infrastructure platform to d...
Just_Super/iStock via Getty Images IREN ( IREN ) reported its Q3‘26 results on May 7, 2026 which showcased that the company’s transition to AI Cloud Services is picking up steam. In addition to a generally well-regarded earnings report for the third fiscal quarter, IREN inked a massive $3.4B, 5-year AI cloud contract with Nvidia ( NVDA ) which is contingent upon the AI infrastructure platform to deploy 600,000 GPUs. Because of this momentum in the company’s core AI Services segment, IREN is adding materially to its annual recurring revenue business which is now expected to hit $3.7B by the end of the year. More deals with large computing companies are likely, leaving significant upside on the table for investors, with regards to both the share price and IREN’s ARR potential. Data by YCharts Previous rating I rated shares of IREN a ‘Strong Buy’ in November 2025 -- Major ARR Uplift Coming - because I liked the platform’s pivot towards high-margin AI Cloud Services. The pivot also implied a high-grading of the platform’s top line and earnings as the company shifted away from cryptocurrency-related mining revenues which tend to be volatile and depend on market conditions that are outside of the control of companies. In the third-quarter, IREN benefited from massive momentum in its AI Cloud Services segment and signed a landmark deal with Nvidia which creates revenue visibility and an expansion of the company’s ARR base. Racing for 10X capacity expansion IREN crushed estimates for its third fiscal quarter on the bottom line, amid strong demand for AI infrastructure services: the Cloud platform reported non-GAAP earnings of $(0.16) per-share, out-matching expectations by a significant $0.18 per-share. Revenues missed expectations by $74M, coming in at $145M. Seeking Alpha IREN generated $114.8M in total revenues in Q3'26, showing a 22% quarter-over-quarter drop-off. This decline in revenues was driven mainly by a correction in the cryptocurrency market, specifically a dec...
First Majestic Silver press release ( AG ): Q1 Non-GAAP EPS of $0.31 in-line. Revenue of $476.7M (95% Y/Y). Cash Flow from Operations ($200.6 million increase Y/Y): Operating cash flow before changes in working capital and taxes in the quarter were $310.6 million or $0.63 per share, a 182% increase compared to $110.0 million or $0.24 per share in the first quarter of 2025. Free Cash Flow ($180.0 m...
First Majestic Silver press release ( AG ): Q1 Non-GAAP EPS of $0.31 in-line. Revenue of $476.7M (95% Y/Y). Cash Flow from Operations ($200.6 million increase Y/Y): Operating cash flow before changes in working capital and taxes in the quarter were $310.6 million or $0.63 per share, a 182% increase compared to $110.0 million or $0.24 per share in the first quarter of 2025. Free Cash Flow ($180.0 million increase Y/Y): The Company generated $223.5 million in free cash flow in the first quarter of 2026 after paying $95.5 million in cash income taxes. Costs: Cash costs and All-in Sustaining Cost ("AISC") per attributable payable AgEq ounce for the quarter were $20.28 and $29.76, respectively, and are anticipated to decrease in the second half of the year. AISC Margin ($38.98 increase Y/Y): The Company generated AISC margin, being the difference between its silver equivalent realized price and AISC, of $52.24 per AgEq ounce, a significant improvement compared to $13.26 per AgEq ounce during Q1 2025. The Company produced 3.5 million silver ounces in Q1 2026 compared to 3.7 million silver ounces produced in Q1 2025, representing 26% of the Company's 2026 silver production guidance midpoint. Gold production was 34,341 ounces in Q1 2026 compared to 36,469 gold ounces produced in Q1 2025, representing 28% of the Company's 2026 gold production guidance midpoint. More on First Majestic Silver Corp. First Majestic Silver: Down From Highs, And I'm Finally Buying First Majestic Silver: Leverage On Silver Works Both Ways (Double Downgrade) First Majestic Silver Corp. 2025 Q4 - Results - Earnings Call Presentation First Majestic Silver Non-GAAP EPS of $0.31 in-line, revenue of $232.8M First Majestic Silver Q1 2026 Earnings Preview
In this article HIMS NVO Follow your favorite stocks CREATE FREE ACCOUNT Piotr Swat | Lightrocket | Getty Images Telehealth company Hims & Hers' stock plummeted in early trading Tuesday after posting a first-quarter loss and weak earnings guidance for the year ahead. The digital health firm reported a net loss of $92 million in its first quarter earnings on Monday, compared with roughly $50 millio...
In this article HIMS NVO Follow your favorite stocks CREATE FREE ACCOUNT Piotr Swat | Lightrocket | Getty Images Telehealth company Hims & Hers' stock plummeted in early trading Tuesday after posting a first-quarter loss and weak earnings guidance for the year ahead. The digital health firm reported a net loss of $92 million in its first quarter earnings on Monday, compared with roughly $50 million for the same period the prior year. Its adjusted Ebitda was $44 million, down from $91 million last year. Meanwhile, revenue was up 4% to $608 million. Average monthly revenue per subscriber was $80, down from $85 last year. Hims is expecting revenue in a range between $680 million and $700 million for the second quarter, and is forecasting up to $3 billion in revenue for the full year. It forecast adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) up to $55 million for the second quarter, and up to $350 million for the full year. The company's stock was last trading down 15.7% in premarket trading. Stock Chart Icon Stock chart icon Hims & Hers shares year to date. Citi analysts described the forecast as "mixed" and noted that Hims & Hers second-quarter outlook came in below Citi's estimates. The analysts also flagged that the first quarter marks a "transition" phase for the company as it reduces its reliance on compounded GLP-1s. Hims reached a deal with Novo Nordisk in March to sell its GLP-1 weight loss drug Wegovy on its platform while committing to stop advertising cheaper copycat versions of the drug known as compounding drugs. Hims stock has often reacted strongly to any news that may affect its ability to sell weight loss drugs to consumers, which has been a highly profitable business for the telehealth company. Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
MOUNTAIN VIEW, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the first quarter ended March 31, 2026, and provided a business update .
MOUNTAIN VIEW, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the first quarter ended March 31, 2026, and provided a business update .
hapabapa/iStock Editorial via Getty Images Novo Nordisk ( NVO ) announced on Tuesday that patients who had an early response to the 7.2 mg version of its obesity therapy Wegovy witnessed additional weight loss over 72 weeks compared to those who received the standard 2.4 mg dose. Earlier this year, U.S. and EU regulators approved the high-dose version of the GLP-1 therapy, also known as semaglutid...
hapabapa/iStock Editorial via Getty Images Novo Nordisk ( NVO ) announced on Tuesday that patients who had an early response to the 7.2 mg version of its obesity therapy Wegovy witnessed additional weight loss over 72 weeks compared to those who received the standard 2.4 mg dose. Earlier this year, U.S. and EU regulators approved the high-dose version of the GLP-1 therapy, also known as semaglutide, as a treatment to lower excess body weight and maintain weight loss in the long term. People who lose 15% or more of their body weight within the first 24 weeks after taking the once-weekly injectable are called early responders to semaglutide. Citing a new analysis from its STEP UP superiority trial designed to evaluate 7.2 mg Wegovy against the 2.4 mg dose and placebo, the Danish drugmaker said that early responders to the higher dose version (about 27% of people) experienced nearly 28% body weight loss. In comparison, early responders to 2.4 mg of semaglutide (about 21%) experienced roughly 25% weight loss. Additional data from the trial indicated that patients on the 7.2 mg dose achieved their weight loss goals faster, shedding 21% of their total body weight over 72 weeks compared to the 17.5% and 2.4% weight loss seen by those on the 2.4 mg version and placebo, respectively. The trial for more than 1,400 obese adults without type 2 diabetes also showed that 7.2 mg of semaglutide caused additional weight loss with a safety and tolerability profile consistent with the lower-dose version, according to Novo ( NVO ). The results were shared at the European Congress on Obesity , taking place in Istanbul, Türkiye, from May 12 to May 15. More on Novo Nordisk A/S Novo Nordisk: Flipping The Script Novo Nordisk: Mixed Q1 Does Not Break The Thesis, But Also Does Not Strengthen It Novo Nordisk: Misread Q1 Earnings, Mispriced Stock Novo Nordisk actively seeking deals to expand pipeline, CEO says Novo Nordisk says oral Wegovy success to soften sales decline
Charles-Édouard Côté Genco Trading & Shipping (DNK) on Tuesday said that Diana Shipping ( DSX ) has made "numerous false, misleading and unsubstantiated claims as part of its hostile campaign" to take over Genco on the cheap. "Do NOT be fooled. Diana is making these statements to distract from the simple truth: Diana is trying to take control of your company without paying full and fair value for ...
Charles-Édouard Côté Genco Trading & Shipping (DNK) on Tuesday said that Diana Shipping ( DSX ) has made "numerous false, misleading and unsubstantiated claims as part of its hostile campaign" to take over Genco on the cheap. "Do NOT be fooled. Diana is making these statements to distract from the simple truth: Diana is trying to take control of your company without paying full and fair value for doing so," Genco said in a statement . The company noted that Diana’s “premium” is based on an arbitrary share price from months before their $23.50 proposal and is irrelevant. The increase in its share price since November has tracked market dynamics, including rising freight rates and asset prices. "Diana is a direct competitor and knows very well that asset values have risen, but they continue to reference stale prices and values as part of their takeover agenda." Genco’s ( GNK ) Board adopted a "limited-duration shareholder rights plan after considerable deliberation and out of necessity in direct response to Diana’s rapid accumulation of Genco stock, which was potentially improperly disclosed," the statement added. Earlier this month Diana Shipping ( DSX ) filed a definitive proxy statement in connection with its nomination of six directors to Genco Shipping ( GNK ) as it battles for a takeover of its dry bulk shipping peer. Diana ( DSX ), which already owns 14.7% of Genco ( GNK ), also filed an open letter to Genco ( GNK ) detailing the company's six-month refusal to engage on Diana's all-cash proposal to purchase Genco for $23.50 a share in cash, according to a statement . Genco's annual meeting is slated for June 18. More on Genco Shipping, Diana Shipping Genco Shipping & Trading Limited 2026 Q1 - Results - Earnings Call Presentation Genco Shipping & Trading Limited (GNK) Q1 2026 Earnings Call Transcript Genco Shipping: Freight Rates Offer Hope, But The Cycle Isn't On Your Side Diana Shipping files definitive proxy statement in battle with Genco (update) Diana Shipp...
Achieve Life Sciences press release ( ACHV ): Q1 GAAP EPS of -$0.19 beats by $0.11 . As of March 31, 2026, the Company's cash, cash equivalents, and marketable securities were $29.3 million, not including estimated net proceeds of approximately $168.6 million from the private placement, after deducting estimated agent fees and other expenses. More on Achieve Life Sciences Achieve Life Sciences: Th...
Achieve Life Sciences press release ( ACHV ): Q1 GAAP EPS of -$0.19 beats by $0.11 . As of March 31, 2026, the Company's cash, cash equivalents, and marketable securities were $29.3 million, not including estimated net proceeds of approximately $168.6 million from the private placement, after deducting estimated agent fees and other expenses. More on Achieve Life Sciences Achieve Life Sciences: The Recent Sell-Off Skews The Outcomes Achieve Life Sciences: Maintaining 'Buy' On Upcoming PDUFA And Expansion Into Vaping Cessation Achieve Life Sciences, Inc. (ACHV) Q4 2025 Earnings Call Transcript Achieve Life Sciences Q1 2026 Earnings Preview Achieve Life Sciences announces private placement of up to $354M
Ovid Therapeutics press release ( OVID ): Q1 GAAP EPS of -$0.12 in-line. Cash, cash equivalents and marketable securities were $165.6 million as of March 31, 2026, which does not include $27.3 million in proceeds received in April 2026 from exercise of Series A warrants More on Ovid Therapeutics Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders - Slidesh...
Ovid Therapeutics press release ( OVID ): Q1 GAAP EPS of -$0.12 in-line. Cash, cash equivalents and marketable securities were $165.6 million as of March 31, 2026, which does not include $27.3 million in proceeds received in April 2026 from exercise of Series A warrants More on Ovid Therapeutics Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders - Slideshow Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding Ovid Therapeutics advances OV329 epilepsy drug, secures $60M financing Seeking Alpha’s Quant Rating on Ovid Therapeutics
Richard Drury/DigitalVision via Getty Images 1stdibs ( DIBS ) reported 1Q26 results, continuing the positive trends seen in 2H25. The company has cut expenses significantly, particularly in marketing, and this has not yet created a very severe impact on growth. GMV is still falling, but not dramatically, while revenues are still holding. Profitability, meanwhile, is improving significantly. This i...
Richard Drury/DigitalVision via Getty Images 1stdibs ( DIBS ) reported 1Q26 results, continuing the positive trends seen in 2H25. The company has cut expenses significantly, particularly in marketing, and this has not yet created a very severe impact on growth. GMV is still falling, but not dramatically, while revenues are still holding. Profitability, meanwhile, is improving significantly. This is a good development. DIBS is moving toward a much more sustainable model, with lower dependency on performance marketing, and the company believes it can return to GMV growth by 4Q26 while attaining an adjusted EBITDA positive figure for the year (first time ever). Despite the above, I continue to believe the name is not particularly attractive at these prices. The stock is cheaper than last quarter , but the company is still far from real profitability on a full GAAP basis, and the full impact of the marketing cuts across the buyer/seller ecosystem is still not visible. I maintain a Hold. 1Q26 results DIBS' 1Q26 was very similar to what we saw in 4Q25, both in terms of the company's trends and in terms of what had been guided. GMV was down 5%, close to the midpoint of guidance. This was expected given the cuts in marketing. Orders were down 12%, and active buyers were down 10%. Revenues were down less than that, only 1%, because take rates had been increased early last year. According to the call, the revenue take rate increased by approximately 120 bps. The most important dynamics, again, happened at the cost level. Gross profit was up 2%, with margins up 2 pp. This improvement came from the higher take rate. Most importantly, OpEx was down 11%. Sales and marketing were down 30%, falling to 28% of revenues from 40% last year. This is the core of the turnaround strategy. The company has cut back significantly on performance marketing. Tech development, on the other hand, was up 10%. G&A was down 2%. The result is that profitability improved quite a lot. Operating losses w...